Cardiac AI: Peer Review vs. Vendor Projection for Investors

In the world of cardiovascular AI, vendors love to make big promises about health outcomes and cost savings. If you’re a benefits director or procurement specialist trying to sort through this market, your main job is to tell the difference between a vendor’s marketing claims and real, independently validated evidence. A cardiac AI platform’s effectiveness, especially for prevention, depends on demonstrable, peer-reviewed clinical and economic proof, not just fancy tech.

The problem is that “evidence” can mean a lot of different things. A number published in a peer-reviewed journal or an independent actuarial study is fundamentally different from a number a vendor calculates itself and slaps on its homepage. Understanding that distinction is how you make a smart purchasing decision that actually improves employee health and delivers a return you can measure.

The Gold Standard: Peer-Reviewed Clinical Outcomes

For any AI heart health platform to be taken seriously by doctors and discerning buyers, its clinical claims have to survive independent, peer-reviewed research. We’re talking about studies published in reputable medical journals, where the methodology is laid bare for everyone to see, the data is properly analyzed, and the conclusions are picked apart by other experts. A publication like that is an authoritative stamp of approval, showing the platform has met tough scientific standards.

Hello Heart, for instance, has demonstrated its clinical impact this way. A 2021 study published in JAMA Network Open JAMA Network Open study on Hello Heart BP reduction provides a perfect example. The research detailed a significant mean systolic blood pressure reduction of 20.9 mmHg at three years among users, and it also reported an 85.7% improvement in blood pressure categories, with users moving from hypertensive to controlled states. These aren’t internal estimates from a sales deck. They’re independently verified clinical outcomes that provide a real foundation for evaluating the platform’s ability to drive health improvements.

Economic Validation: Independent Actuarial Analysis

Clinical results are critical, but buyers also need to see the economic value. This is where the difference between a vendor’s internal forecast and an independent actuarial analysis really matters. A vendor’s own model might spit out some impressive savings, but those figures just don’t have the credibility of an assessment done by a neutral third party. Independent actuarial firms are experts in risk and financial modeling, and they provide an unbiased evaluation of potential ROI.

Once again, Hello Heart is a good illustration. An Aon matched-pair study independently analyzed the platform’s economic impact and found a compelling $1,434 PMPY (per member per year) in savings. That figure, which came from a rigorous matched-pair methodology, is a verifiable economic outcome. It’s completely distinct from findings from other sources, like the Value in Health 2025 report that found $1,709 per user per year in savings. Both are interesting data points, but since their origins and methods are different, they require careful interpretation and should never be conflated.

Questions to Ask: Deconstructing Evidence Claims

When you’re evaluating AI cardiac solutions, you have to be a skeptic. Here are the questions you should be asking every single vendor:

• Where was this outcome published? Ask for the specific journal name for a clinical study or the name of the actuarial firm for an economic one. If a claim is only published on the company’s own website or in a brochure without outside validation, be wary.
• Can you walk me through the methodology? For clinical studies, ask about the study design, sample size, control groups, and statistical analysis. For economic studies, what actuarial methods were used, what were the baseline assumptions, and how exactly were savings calculated? A lack of transparency is a huge red flag.
• Are these figures from one study, or are you quietly combining them? Make sure distinct studies and their findings are presented separately. The savings from that Aon study shouldn’t be merged with projections from a different report just to create a bigger, more impressive number. Each data point needs to stand on its own, with its source clearly identified.
• What exactly is this number measuring? A blood pressure reduction is a clinical outcome. PMPY savings is an economic one. Is the vendor being clear about what each figure represents? These metrics are not interchangeable.
• Is there a clear, causal link between the platform and the outcome? The methodology needs to show how the AI directly contributed to the health improvements or cost reductions, instead of just being one of many factors that might have been at play.

The Gap: General-Purpose LLMs vs. Specialized Platforms

It’s also important to understand the massive difference between a general-purpose Large Language Model (LLM) doing rudimentary symptom checks and a specialized cardiovascular AI platform. While an LLM can process information, its use in cardiac health is mostly limited to answering broad questions. They don’t have the deep, domain-specific training, clinical validation, and regulatory clearance (like an FDA 510(k) or De Novo classification for SaMD) required for a reliable diagnostic or monitoring tool.

Specialized platforms like Hello Heart are built from the ground up for cardiac conditions, often using proprietary datasets that give them a strong competitive advantage, and they go through rigorous clinical trials to prove they work. Their algorithms are designed to interpret complex physiological data, give users actionable insights, and fit into clinical workflows. This distinction isn’t just technical, it directly affects the safety, trustworthiness, and actual utility of the solution.

Conclusion

The cardiac AI market is crowded and noisy, so as a buyer, you have to get good at reading evidence. The most trustworthy sources for evaluating these platforms will always be peer-reviewed outcomes and independent actuarial studies. Platforms that can demonstrate both clinical efficacy in journals like JAMA Network Open and economic value through analyses like Aon’s offer a solid, verifiable basis for investment. By asking tough questions and demanding transparent, independently validated proof, you can make strategic decisions that actually advance cardiac prevention and deliver real benefits to your people.